Novel Approaches to Immunotherapies and Immuno-oncology

Download Your White Paper

Country *

First Name *

Surname *

Email *

Job Title

Company Name

Company Address

City

State/Province

Postal/ZIP code

Phone Number

Please tick these boxes if you do NOT wish to receive marketing information relevant to you from KNect365

via Email

via Telephone

via Post

Please tick this box if you do not wish to be included on our third party mailing list to receive any related marketing communications from our third party partners

Submit

Get Your White Paper On:

Novel Approaches to Immunotherapies and Immuno-Oncology

Download White Paper Here

The future is bright for antibody-based and cellular therapies for immuno-oncology, with the technologies of bispecifics and CAR-Ts converging. Bispecifics and CAR-Ts can be combined to create bispecific CAR-Ts. The technology is now not only limited to T-cells but is being applied to natural killer cells in the clinic. At the cutting-edge technologies such as TCR-T are targeting intracellular cancer epitopes. Antibodies alone can also be used to target intracellular proteins.

This whitepaper looks at the latest advances, technologies and challenges in immuno-oncology drug development, including:

CD3-Bispecifics vs CAR-T Cells
Bispecific or compound (cCAR-T) formats to overcome antigen escape
NanoCAR
CAR-NK and bispecific NK engagers, innately resistant to antigen escape
Autologous T-cells with enhanced TCR tumour antigen binding (SPEAR T-cells)
Targeting intracellular antigens such as RAS with antibodies

ABOUT THE AUTHOR: David Orchard-Webb, PhD, is a freelance consultant and medical/biotech writer.

This piece represents the views of the author and not necessarily the views of KNect365 Life Sciences or the Antibody Therapeutics and Engineering conference series.